?Effect of human Chorionic Gonadotropin (hCG) on treatment of infertility

The effect of adding low dose human Chorionic Gonadotropin (hCG) to recumbinant Follicular Stimulating Hormone (rFSH) on follicular phase in women undergoing intracytoplasmic sperm injection cycle, a clinical trial.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017012932284N1

Enrollment

150

Registered

2017-03-07

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility. Female infertility associated with anovulation

Interventions

Intervention 1: In the first group patients treated with a dose of 150 International Unit (IU) recombinant Follicular Stimulating Hormone (rFSH) per day. Treatment with rFSH will continue until the cr

100 IU human Chorionic Gonadotropin (hCG) will inject. Thirty six hours later ovarian puncture is performed. Intervention 2: In the second group patients treated with a dose of 150 International Unit

100 IU hCG will inject. Thirty six hours later ovarian puncture is performed. Intervention 3: In the third group patients treated with a dose of 150 International Unit (IU) recombinant Follicular Stim

100 IU hCG will inject. Thirty six hours later ovarian puncture is performed.

Treatment - Drugs

In the first group patients treated with a dose of 150 International Unit (IU) recombinant Follicular Stimulating Hormone (rFSH) per day. Treatment with rFSH will continue until the creation of the oo

100 IU human Chorionic Gonadotropin (hCG) will inject. Thirty six hours later ovarian puncture is performed

In the second group patients treated with a dose of 150 International Unit (IU) recombinant Follicular Stimulating Hormone (rFSH) per day. When the follicle size become 14 millimeter, rFSH dose reduce

In the third group patients treated with a dose of 150 International Unit (IU) recombinant Follicular Stimulating Hormone (rFSH) per day. When follicle size become 14 millimeter, treatment with rFSH s

Eligibility

Sex/Gender

Female

Age

20 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 20 - 40 years old; 1 year history of infertility; candidate for intracytoplasmic sperm injection. Exclusion Criteria: history of chronic disease; abnormal salpingography.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Follicle size. Timepoint: Daily. Method of measurement: Ultrasonography - Milimeter.;Mature oocyte. Timepoint: End of Cycle. Method of measurement: Sonography.	—

Secondary

Measure	Time frame
Ovarian Hyperstimulation Syndrome. Timepoint: Daily. Method of measurement: Sonography - Folicle size - Milimeter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Maryam Yeganegi

Babol University of Medical Science

parastoo0847@yahoo.com+98 11 3227 4880

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026